Aleksandra Petrovic Fabijan
Overview
Explore the profile of Aleksandra Petrovic Fabijan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrovic Fabijan A, Iredell J, Danis-Wlodarczyk K, Kebriaei R, Abedon S
PLoS Biol
. 2023 May;
21(5):e3002119.
PMID: 37220114
Phage therapy is a medical form of biological control of bacterial infections, one that uses naturally occurring viruses, called bacteriophages or phages, as antibacterial agents. Pioneered over 100 years ago,...
2.
Raseta M, Miskovic J, capelja E, Zapora E, Petrovic Fabijan A, Knezevic P, et al.
Molecules
. 2023 Apr;
28(7).
PMID: 37050027
species have been recognized as potential antimicrobial (AM) agents and have been used in traditional Chinese medicine (TCM) for a long time. The aim of this study is to examine...
3.
Nang S, Lin Y, Petrovic Fabijan A, Chang R, Rao G, Iredell J, et al.
Clin Microbiol Infect
. 2023 Feb;
29(6):702-709.
PMID: 36736661
Background: The increasing emergence of antimicrobial resistance worldwide has led to renewed interest in phage therapy. Unlike antibiotics, the lack of pharmacokinetics/pharmacodynamics (PK/PD) information represents a major challenge for phage...
4.
Petrovic Fabijan A, Martinez-Martin D, Venturini C, Mickiewicz K, Flores-Rodriguez N, Errington J, et al.
Microbiol Spectr
. 2022 Sep;
10(5):e0241922.
PMID: 36102643
Cell wall deficient bacterial L-forms are induced by exposure to cell wall-targeting antibiotics and immune effectors such as lysozyme. L-forms of different bacteria (including Escherichia coli) have been reported in...
5.
Venturini C, Petrovic Fabijan A, Lubian A, Barbirz S, Iredell J
EMBO Mol Med
. 2022 May;
14(7):e12435.
PMID: 35620963
Bacteriophages (phages) are selective viral predators of bacteria. Abundant and ubiquitous in nature, phages can be used to treat bacterial infections (phage therapy), including refractory infections and those resistant to...
6.
Knezevic P, Petrovic Fabijan A, Gavric D, Pejic J, Doffkay Z, Rakhely G
Viruses
. 2021 Oct;
13(10).
PMID: 34696396
The applicability and safety of bacteriophage Delta as a potential anti- agent belonging to genus (family ) was characterised. Phage Delta belongs to the species , which has been described...
7.
Petrovic Fabijan A, Aleksic Sabo V, Gavric D, Doffkay Z, Rakhely G, Knezevic P
Viruses
. 2021 Sep;
13(9).
PMID: 34578315
is a respiratory animal pathogen that shows growing resistance to commonly used antibiotics, which has necessitated the examination of new antimicrobials, including bacteriophages. In this study, we examined the previously...
8.
Petrovic Fabijan A, Lin R, Ho J, Maddocks S, Ben Zakour N, Iredell J
Nat Microbiol
. 2020 Mar;
5(4):652.
PMID: 32139910
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
9.
Petrovic Fabijan A, Lin R, Ho J, Maddocks S, Ben Zakour N, Iredell J
Nat Microbiol
. 2020 Feb;
5(3):465-472.
PMID: 32066959
In this single-arm non-comparative trial, 13 patients in an Australian hospital with severe Staphylococcus aureus infections were intravenously administered a good manufacturing practice-quality preparation of three Myoviridae bacteriophages (AB-SA01) as...
10.
Petrovic Fabijan A, Khalid A, Maddocks S, Ho J, Gilbey T, Sandaradura I, et al.
Med J Aust
. 2019 Oct;
212(6):279-285.
PMID: 31587298
Bacteriophage (phage) therapy is re-emerging a century after it began. Activity against antibiotic-resistant pathogens and a lack of serious side effects make phage therapy an attractive treatment option in refractory...